Professor Christian Bréchot joined the Institut Pasteur as its President on October 1, 2013. He had served as Vice President of Medical and Scientific Affairs for Institut Mérieux, where he helped oversee diverse research projects ranging from infectious disease to cancer.
Prior to this, Professor Bréchot was General Director of Inserm, the French National Agency for biomedical research. He obtained his Ph.D in biochemistry from the University of Paris VII and an MD from Broussais Hôtel Dieu School of Medicine, Paris. In 1989 he became full professor of Cell Biology and Hepatology, and in 1997 he was appointed head of the clinical department of liver diseases at the Necker-Enfants Malades Hospital.
Professor Bréchot's research focuses on viral hepatitis, hepatitis B (HBV) and C (HCV), particularly with regard to their role in liver cancer. The author of over 350 articles, Dr. Bréchot's research has led to 13 patents and contributed to the creation of two biotech companies.
Currently the principal of Deborah A. Nilson, PLLC, a law firm she founded in 2006, Deborah Nilson is a member of the New York State Bar, the Bars of the United States District Courts of the Southern, Eastern and Northern Districts of New York, and the Bar of the Supreme Court of the United States.
She began her career at the law firm of Richard K. Bernstein Associates, where she practiced corporate law and began working with a French-speaking clientele. In 1989, she co-founded the law firm Rozan & Nilson LLP.
Ms. Nilson holds a B.S. from Syracuse University and a J.D. from New York Law School.
Dr. Mireille Gillings is the founder, President, CEO and Executive Chair of HUYA Bioscience International, the privately held global leader in accelerating development of biopharma innovation originating in China. Dr. Gillings is a pioneer in establishing extensive collaborations with Chinese academic institutions and commercial organizations to create value in worldwide markets for China-sourced biopharma compounds. As a visionary leader with 20 years’ experience in the biotech sector – including drug development, preclinical study design and academic partnering programs – Dr. Gillings has made substantial contributions to neurological and neurodegenerative disease research, including a focus on neuroactive steroids.
Dr. Gillings serves on the board of directors of Quintiles (NYSE: Q), a Fortune 500 company and the world’s largest provider of biopharmaceutical development and commercial outsourcing services. She is the first woman appointed to the board of Quintiles since the company’s privatization and subsequent IPO. In addition, she is Co-founder and non-Executive Vice Chair of GHO Capital, a European private equity fund specializing in global health opportunities; and serves on the Board of Directors of Senté Inc, a private science-based skincare company.
Educated in Canada, the Netherlands, France, and the USA, Dr. Gillings has a Ph.D. in neuroscience from Radboud University Nijmegen and has completed post-doctoral fellowships at Bordeaux University and Scripps Research Institute. She speaks fluent English, Dutch, French and Spanish.
Mr. Legorreta founded Royalty Pharma in 1996, after creating and managing two “proof of principle” investment vehicles in 1993 and 1994 that invested in royalty interests in two leading biotechnology products. Prior to founding these investment vehicles, Mr. Legorreta spent ten years at Lazard Frères where he provided cross-border merger and acquisition and corporate finance advisory services to US and European corporations. Mr. Legorreta joined Lazard Frères et Cie in Paris in 1988, then moved to Lazard Frères & Co in New York in 1990.
Mr. Legorreta currently serves as a Director of Giuliani SpA and is a founding member of Boston Children’s Hospital Medical Research Council, as well as a member of the Board of Trustees of The Allen-Stevenson School. He received a degree in industrial engineering from Universidad Iberoamericana.
At Evercore, Mr. Maisonrouge was involved in advising Wyeth on its sale to Pfizer, Sanofi-aventis on its purchase of Merck’s 50% stake in Merial including an option to potentially merge Merial with Intervet / Schering-Plough Animal Health in the future, TPG on its acquisition of IMS Health, De Ruiter on its sale to Monsanto, Bracco on its acquisition of E-Z-Em, and the sale of Optonol to Alcon.
Prior to joining Evercore, Mr. Maisonrouge was a Managing Director and Chairman of Life Sciences at Credit Suisse where he worked extensively in the fields of pharmaceuticals, specialty pharmaceuticals, biotechnology and medical technology. At Credit Suisse, Mr. Maisonrouge was responsible for leading the firm’s relationships with large healthcare clients such as Johnson & Johnson, Schering-Plough, Wyeth, GlaxoSmithKline, Roche and Teva, most notably in executing mergers and acquisitions and capital raising transactions.
Mr. Maisonrouge has an M.S. in Engineering from Ecole Centrale de Lyon and an M.B.A. from Harvard Business School. He is a member of the Board of Advisors of the Harvard Business School Health Care Initiative, and was awarded France’s “Ordre National du Merite” in 2003. In 2014, Mr. Maisonrouge was awarded the rank of Chevalier de la Légion d'honneur. He resides in New York City.
Mr. Wirz managed global portfolios for individuals, families and their foundations while a Managing Director of Fiduciary Trust from 1982-2013. He also served as head of the Income Strategy Committee, and the Global Equity Strategy Committee.
Prior to joining Fiduciary Trust, Mr. Wirz spent 11 years at the European American Economic Corporation as an analyst and investment advisor. In addition to serving on the Pasteur Foundation American Advisory Board, he serves as a director of the Corlette Glorney Foundation.
A graduate from the Hautes Études Commerciales, Paris (1965), Mr. Wirz obtained a “Licence” in economics from The University of Paris (1966) and earned an M.B.A. from Lehigh University (1968).